The most anticipated moment arrived on May 21 at the STOA auditorium in Cancun, where HIPRA revealed, in a private event, the details of the new range of vaccines that represent a significant progress in the prevention of major viral diseases in cattle.

More than 300 attendees were able to learn firsthand about the solutions these new vaccines offer. The event, which featured Dr. C. Chase, a renowned American immunologist, addressed the major viral diseases that cause the most problems for veterinarians (IBR, BVD, BRSV, and PI3), distinguishing the “two worlds,” referring to two realities with different prevention strategies: Europe, with control and eradication plans for BVD and IBR; and America and the rest of the world, where the strategy focuses on preventing clinical presentations of these viruses.

Héctor Santo Tomás, Global Franchise Manager of HIPRA, explained the "paradigm shift" that DIVENCE® represents: "To begin with, it offers the highest standards of safety and efficacy against the most relevant respiratory and reproductive viruses in cattle" and it is "for the first time a multivalent vaccine marked for IBR and BVD."

After decades where the obsession has been to prevent diseases and controlling the circulation of the virus on the farm was more of a dream than a reality, " DIVENCE®, being marked for IBR and BVD, allows veterinarians for the first time to have greater control precisely in this second objective." Héctor concluded that "through a single tool, veterinarians and farmers around the world, beyond preventing disease, will be able to ensure better decision-making regarding the control of these viruses’ circulation."

Neither live nor inactivated

The following day, the Gran Cancun Hall at the World Buiatrics Congress hosted the HIPRA Symposium, displaying a full house sign with more than 400 attendees. There, the technical aspects of controlling these viruses and details of the vaccine were explained in depth, such as the new category of vaccines to which the DIVENCE® range belongs, deviating from the traditional classification of live or inactivated for BVDV, being in this case a new group of vaccines, recombinant protein.

Throughout much of the week, the HIPRA DIVENCE ® booth offered various sessions open to all congress attendees on viral disease control in different regions of the world, the necropsy technique as a diagnostic tool, as well as the results obtained in fattening using DIVENCE®, among others.

Following the global launch, HIPRA's new range of vaccines will be presented locally in several countries over the coming months.

DIVENCE ® is the best example of HIPRA's firm commitment to evolving hand in hand with the veterinary community, providing it with tools that not only serve to prevent disease but also mark a before and after in the way of working. The development of this range of vaccines has sought from the outset to offer that extra to transform the ordinary into the extraordinary.